Antiphospholipid syndrome: long-time research on pathogenic mechanisms has finally lead to new therapeutic strategies

被引:5
作者
Cervera, Ricard [1 ]
Espinosa, Gerard [1 ]
机构
[1] Hosp Clin Barcelona, Dept Autoimmune Dis, Inst Clin Med & Dermatol, E-08036 Barcelona, Catalonia, Spain
关键词
anticardiolipin antibodies; antiphospholipid syndrome; lupus anticoagulant; TISSUE FACTOR EXPRESSION; ENDOTHELIAL-CELLS; ANTIBODIES; ACTIVATION; PATHWAY;
D O I
10.1517/14728222.2010.530900
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The antiphospholipid syndrome is characterized by the presence of arterial or venous thrombosis or recurrent miscarriages in a patient with positive laboratory tests for antiphospholipid antibodies (anticardiolipin antibodies and/or lupus anticoagulant and/or anti-beta2-glycoprotein I). Despite the strong association between antiphospholipid antibodies and thrombosis and obstetric morbidity, their pathogenic role in the development of these clinical features has not been fully elucidated. However, the knowledge of new pathogenic mechanisms might identify novel therapeutic targets and therefore may improve the management of these patients.
引用
收藏
页码:1279 / 1282
页数:4
相关论文
共 20 条
  • [1] Antiphospholipid syndrome -: Clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients
    Cervera, R
    Piette, JC
    Font, J
    Khamashta, MA
    Cervera, R
    Piette, JC
    Font, J
    Khamashta, MA
    Shoenfeld, Y
    Camps, MT
    Jacobsen, S
    Lakos, G
    Tincani, A
    Kontopoulou-Griva, I
    Galeazzi, M
    Meroni, PL
    Derksen, RHWM
    de Groot, PG
    Gromnica-Ihle, E
    Baleva, M
    Mosca, M
    Bombardieri, S
    Houssiau, F
    Gris, JC
    Quéré, I
    Hachulla, E
    Vasconcelos, C
    Roch, B
    Fernández-Nebro, A
    Boffa, MC
    Hughes, GRV
    Ingelmo, M
    [J]. ARTHRITIS AND RHEUMATISM, 2002, 46 (04): : 1019 - 1027
  • [2] Management of the obstetric antiphospholipid syndrome
    Derksen, RHWM
    Khamashta, MA
    Branch, DW
    [J]. ARTHRITIS AND RHEUMATISM, 2004, 50 (04): : 1028 - 1039
  • [3] Edwards MH, 1997, CIRCULATION, V96, P4380
  • [4] Antiphospholipid syndrome: pathogenic mechanisms
    Espinosa, G
    Cervera, R
    Font, J
    Shoenfeld, Y
    [J]. AUTOIMMUNITY REVIEWS, 2003, 2 (02) : 86 - 93
  • [5] Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells
    Ferrara, DE
    Swerlick, R
    Casper, K
    Meroni, PL
    Vega-Ostertag, ME
    Harris, EN
    Pierangeli, SS
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (09) : 1558 - 1563
  • [6] Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor
    Fischetti, F
    Durigutto, P
    Pellis, V
    Debeus, A
    Macor, P
    Bulla, R
    Bossi, F
    Ziller, F
    Sblattero, D
    Meroni, P
    Tedesco, F
    [J]. BLOOD, 2005, 106 (07) : 2340 - 2346
  • [7] Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation
    Girardi, G
    Redecha, P
    Salmon, JE
    [J]. NATURE MEDICINE, 2004, 10 (11) : 1222 - 1226
  • [8] B cell depletion therapy for patients with systemic lupus erythaematosus results in a significant drop in anticardiolipin antibody titres
    Ioannou, Y.
    Lambrianides, A.
    Cambridge, G.
    Leandro, M. J.
    Edwards, J. C. W.
    Isenberg, D. A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (03) : 425 - 426
  • [9] KORNBERG A, 1994, J IMMUNOL, V153, P1328
  • [10] Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-κB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK pathway
    López-Pedrera, C
    Buendía, P
    Cuadrado, MJ
    Siendones, E
    Aguirre, MA
    Barbarroja, N
    Montiel-Duarte, C
    Torres, A
    Khamashta, M
    Velasco, F
    [J]. ARTHRITIS AND RHEUMATISM, 2006, 54 (01): : 301 - 311